CClinicalTrials.gg
RecruitingNCT03803735RFAOPUpdated Oct 3, 2025

Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa

An observational study in Pediatric Cancer, sponsored by French Africa Pediatric Oncology Group. Recruiting at 14 sites in 12 countries. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by French Africa Pediatric Oncology Group · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
1 Day to 18 Years
Sex
All
01

Study summary

The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population.

Collecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.

Read the detailed description

This register is a registration of all children entering hospital based pediatric oncology units, working in selected hospitals in French speaking Africa. The data collected includes: demographic and socioeconomic status as well as clinical status and outcome.

The register also collects information on vital status, treatment abandonment and loss to follow-up.

Data, collected locally is entered on line using the Research Electronic Data Capture (REDCap) program. Data are stored under the responsibility of the IT department at Gustave ROUSSY in Paris- Villejuif.

02

Conditions studied

  • Pediatric Cancer

Browse trials for

03

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All childre with any pediatric cancer types, coming into any one of the participating units in a 12 month period.

Inclusion criteria

  1. Any child presenting at any one of the participating units for treatment
  2. Any child with any type of cancer
  3. Any child or adolescent less than 18 years of age.

Exclusion criteria

Exclusion Criteria:

  1. No cancer found
  2. Age greater than 18 years -
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
05

What researchers measure

Primary outcomes

  1. Number of children with a suspicion of any type of cancer in a given unit

    Number of children with details of : 1. the type of cancer 2. the stage of the identified cancer coming into a given unit

    Time frame: in any 12 month period

  2. VITAL STATUS:

    Dead or alive 1. The number of children living 2. the number of children dead

    Time frame: in any 12 month period

  3. Illness status

    1. The number of children relapsed, 2. The number of children whos illness has progressed.

    Time frame: in any 12 month period

  4. Treatment Status

    1. The number of children who had treatment administered, 2. The number of children who abandoned treatment

    Time frame: in any 12 month period

06

Study locations

14 of 14 sites recruiting
  • Hopital Yalgado Ouedraogo
    Ouagadougou, 03 BP 7022, Burkina Faso
    • BOUDA CHANTAL, DR · Contact
    Recruiting
  • Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle
    Ouagadougou, Burkina Faso
    • Sonia Ms Kaboret, Dr · Contact
    • kawajo200046@gmail.com · Contact
    Recruiting
  • Centre Mère et Enfant CME-FCB (Fondation Chantal Biya)
    Yaoundé, Cameroon
    Recruiting
  • CHU de Treichville à ABIDJAN
    Abidjan, Abidjan Autonomous District, Côte d’Ivoire
    • Line Guei COUITCHERE, MD · Contact
    Recruiting
  • Cliniques Universitaires de Kinshasa
    Kinshasa, Kinshasa City BP 12 KIN XI, Democratic Republic of the Congo
    • BUDIONGO Aléine, DR · Contact
    Recruiting
  • Cliniques Universitaires de Lubumbashi (CUL)
    Lubumbashi, BP 1825, Democratic Republic of the Congo
    Recruiting
  • GFAOP
    Villejuif, PARIS 00094, France
    Recruiting
  • l'Institut de Cancérologie de Libreville
    Libreville, Gabon
    • Betty NDAKISSA, DR · Contact
    Recruiting
  • HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona
    Antananarivo, Ampefiloha BP 4150, Madagascar
    Recruiting
  • CHU Gabriel Touré (HGT)
    Bamako, Mali
    Recruiting
  • Centre National d'Oncologie (CNO)
    Nouakchott, Mauritania
    • Ekhtel Benina ZEIN, DR · Contact · 222 45 24 22 32
    Recruiting
  • CNLC, Centre National de Lutte contre le Cancer
    Niamey, Niger
    • Aichatou MAHAMADOU, DR · Contact
    Recruiting
  • Hôpital Aristide Le Dantec, Avenue Pasteur, BP 3001
    Dakar, Dakar, Senegal
    Recruiting
  • CHU Sylvanus Olympio
    Lomé, BP 57, Togo
    • Koffi Mawuse Jules GUEDENON, DR · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided — Units have acess to their own data and can use it for reporting.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03803735
Lead sponsor
French Africa Pediatric Oncology Group
Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Responsible party
Sponsor
First posted
Jan 15, 2019
Start date
Jan 1, 2016
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 3, 2025

Study contacts

Brenda MALLON, MSC
Contact
brenda.mallon@gustaveroussy.fr
+ 33142115411
Catherine PATTE, DR
Contact
catherine.patte@gustaveroussy.fr
+ 33142116560
Brenda Mallon, MSc
study director · French Africa Pediatric Oncology Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion